Advertise on podcast: Inside Modern Biotech

The asteroid Ryugu is a small, dark, spinning-top-shaped rock about 900 metres wide, orbiting the Sun in a path that crosses between Earth and Mars. It is a C-type asteroid, meaning it is carbon-rich, ancient, and chemically primitive. C-type asteroids are believed to be some of the most pristine material in the solar system: bodies that formed 4.6 billion years ago during the birth of the planets and have changed very little since, preserved in the cold of space far from the chemical processing that reshaped the rocky planets.

Researchers in Brazil ran a randomized controlled trial on 80 women undergoing chemotherapy for breast cancer. One group took 2,000 IU of vitamin D daily. The other took a placebo. After six months, 43% of the vitamin D group had no cancer left by the time of surgery. In the placebo group, only 24% did. That is a 79% relative difference. From a supplement that costs a few dollars a month. In this episode, we break down what the study actually found, why the numbers need careful reading, and what a second independent trial from Turkey with 227 patients adds to the picture. We explain what vitamin D actually does inside cancer cells: how it pushes them toward self-destruction, cuts off their blood supply, and may make chemotherapy more effective. We also cover why so many breast cancer patients are deficient before treatment even begins, what dose was used and why it is considered safe, and what needs to happen before this changes standard clinical practice. This is not a story about a miracle supplement. It is a story about a real signal in real data, a biologically plausible mechanism, and what it could mean for patients in health systems where expensive cancer drugs are out of reach. Source: Omodei et al., Nutrition and Cancer, 2025. DOI: 10.1080/01635581.2025.2480854 Supporting: Özkurt et al., World Journal of Surgery, 2025. DOI: 10.1002/wjs.12587

In 1859, Darwin predicted the fossil record would reveal creatures caught mid-evolution. Two years later, workers in a German quarry found one: feathers of a bird, teeth of a lizard. They called it Archaeopteryx. For 164 years, one question stayed unanswered: could it actually fly? In this episode, we walk through the Chicago Archaeopteryx — the 14th and smallest known specimen, acquired by the Field Museum in 2022, still encased in rock. After 1,300 hours of preparation using UV light and CT scanning, what emerged was unlike anything seen in 160 years of study. We cover the soft tissue glowing under UV. The tertial feathers that finally settled the flight debate. What the roof of the mouth tells us about how rigid dinosaur skulls became the nimble, kinetic structures of modern birds. And the finding hiding beneath it all: flight may have evolved not once, but multiple times across the dinosaur family tree. A 150-million-year-old animal. A 165-year argument. The moment science finally got a good enough look to settle it. Source: O’Connor et al., Nature, May 2025. DOI: 10.1038/s41586-025-08912-4

Lipid nanoparticles made headlines as the delivery vehicle behind COVID-19 mRNA vaccines, but their story goes far beyond the pandemic. Join us as we explore how these microscopic fat bubbles are transforming medicine from gene therapy and cancer treatment to the next generation of vaccines. We’ll break down the science, meet the researchers pushing boundaries, and discover why these nanoscale couriers might be the key to treating diseases once thought incurable.

In this episode of Inside Modern Biotech, we dive into how AI is transforming protein science through tools like AlphaFold and AlphaFold 3. We’ll explore how these models can “fold” proteins in silicon from just their amino acid sequence, what that means for understanding disease, and how it’s speeding up drug discovery and protein design. From basic folding concepts to real-world applications in the lab, this episode is your guided tour of the AI revolution in structural biology.

CRISPR-Cas9 is a gene-editing system adapted from a bacterial immune defense that lets scientists cut and rewrite DNA at precise locations using a programmable guide RNA and the Cas9 “molecular scissors.” Once Cas9 makes a break in the DNA, the cell’s own repair machinery either stitches it back together in an error-prone way (knocking genes out) or uses a supplied template to make precise changes. On top of classic Cas9, newer tools like base editors and prime editors can rewrite single letters or small stretches of DNA without making full double-strand breaks. This toolkit has completely changed biology: it’s now routine to switch genes on or off, build disease models, engineer crops and livestock, and run massive genetic screens. In medicine, CRISPR has moved from the lab to the clinic, with a focus on somatic (non-heritable) edits delivered either ex vivo (cells edited outside the body and reinfused) or in vivo (directly into patients, often via lipid nanoparticles or viral vectors). Safety issues—off-target edits, complex DNA rearrangements, immune reactions, and delivery-related toxicity—are active areas of research and regulation. Headline CRISPR treatments so far: Casgevy (exa-cel) – first approved CRISPR therapy (US, UK, others) for sickle cell disease and β-thalassemia, by editing blood stem cells ex vivo to turn back on fetal hemoglobin.NTLA-2001 – in vivo CRISPR knock-out of the TTR gene for transthyretin amyloidosis; showed huge TTR reductions but is now under FDA clinical hold after a serious liver toxicity case.EDIT-101 – subretinal CRISPR for an inherited blindness (LCA10), with many participants showing meaningful vision improvements.Custom CPS1 base-editing therapy – a one-off CRISPR base-editing treatment designed for a single baby with a lethal metabolic disorder.Cardiovascular base editing (e.g., VERVE-101, ANGPTL3 programs) – one-time in vivo edits in the liver to permanently lower LDL and triglycerides.CRISPR-engineered immune cells – T cells with PD-1 knocked out or multiplex-edited CAR-T cells for cancer immunotherapy. At the same time, the controversial case of gene-edited babies (germline CCR5 edits) has led to strong global consensus that heritable embryo editing is off-limits for now, while carefully regulated somatic CRISPR therapies continue to expand.